No Data
No Data
Zenas BioPharma Reports Strong 2024 Momentum, Eyes 2025 Milestones In Obexelimab Trials for Lupus, Multiple Sclerosis, And IgG4-RD
Express News | Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026
Express News | Zenas Biopharma : Topline Results From Phase 2 Trial in Relapsing Multiple Sclerosis (Moonstone) Expected in Q3 2025
Wolfe Research Initiates Zenas BioPharma(ZBIO.US) With Buy Rating, Announces Target Price $19
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session